Insider Trading Arrangements

9 Months Ended

Sep. 30, 2025

Trading Arrangements, by Individual [Table]

Material Terms of Trading Arrangement [Text Block]

ITEM 5. OTHER INFORMATION

During the three months ended September 30, 2025, no director or officer, as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K. 

On  July 11, 2025, two short term promissory notes of $150 thousand each were issued by the Company’s majority-owned subsidiary KardioNav to David Jenkins, the Company's Chairman of the Board and Chief Executive Officer, and Lifestim, Inc., a company controlled by Mr. Jenkins, in exchange for an aggregate loan of $300 thousand. The promissory notes have a maturity date of  July 11, 2026, and interest rates of 4.2% per annum, with all principal and interest payable upon maturity.  As of September 30, 2025, $300 thousand of principal was outstanding on the notes.

The notes, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owed when due, material breach of the Company’s representations or warranties (unless waived by the holders or cured within 10 days following notice), certain events involving the discontinuation of the Company’s business and/or certain types of proceedings involving insolvency, bankruptcy, receivership and the like.

Rule 10b5-1 Arrangement Terminated [Flag]

false

Rule 10b5-1 Arrangement Adopted [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false